Every few months, a new COVID variant name pops into the news feed, and the latest making headlines in 2026 is BA 3.2, nicknamed the Cicada variant. This article breaks down what we actually know about its symptoms, how long it lasts, and whether it’s any different from the cold you might have had last week, drawing on the latest guidance from the NHS and ECDC.

4 related posts

Dominant variant as of mid-2026: BA 3.2 (Cicada), an Omicron sublineage ·
Key symptoms reported: sore throat, runny nose, cough, fatigue, fever ·
Severity vs prior variants: generally milder but highly transmissible ·
Estimated duration of illness: 3–7 days for most, longer for high-risk

Quick snapshot

1Confirmed facts
2What’s unclear
3Timeline signal
  • First detected: early 2026 (CDC MMWR) (ECDC)
  • Became dominant in several regions by spring 2026 (NewYork-Presbyterian) (ECDC)
  • ECDC classified as variant under monitoring (VUM) (ECDC)
4What’s next
  • Continued monitoring by CDC and ECDC (Global Virus Network)
  • Possible winter wave later in 2026 (AARP)
  • Updated vaccines may be adapted if needed (CDC MMWR)

Six key facts about BA 3.2, straight from official surveillance reports and health authority briefings:

Fact Detail
Variant designation BA 3.2 (Omicron sublineage)
Common name Cicada variant
First detected Early 2026
Current status (ECDC) Variant under monitoring (VUM)
Most common symptom Sore throat
Typical duration 3–7 days

What are the symptoms of the new COVID strain?

Common symptoms of the BA 3.2 (Cicada) variant

  • Sore throat (NewYork-Presbyterian)
  • Runny nose or congestion (Stony Brook Medicine)
  • Persistent cough (AARP)
  • Fatigue or low energy (NewYork-Presbyterian)
  • Fever or chills (Stony Brook Medicine)
  • Headache (NewYork-Presbyterian)

One notable difference from earlier pandemic strains: loss of taste or smell is now reported less often. According to Clinikk, it is still possible but far from the hallmark symptom it once was.

Symptoms that differ from earlier strains

The upshot

The BA 3.2 symptom list reads almost exactly like a cold. What sets it apart is the occasional fever and the rare loss of smell — but without a test, you’ll struggle to tell the difference.

Stony Brook Medicine notes that BA 3.2 does not cause new or unusual symptoms compared with other recent Omicron subvariants. If you’re monitoring a fever, here is a quick guide to converting Celsius to Fahrenheit.

The implication: the symptom picture is stable — no surprises, but also no easy shortcut to diagnosis.

If you have symptoms, testing is the only reliable way to confirm BA 3.2, as it feels like a cold but may include fever. Rely on a rapid test, not guesses.

What is the newest strain of COVID called?

Official designation: BA 3.2

  • BA 3.2 is an Omicron sublineage (CDC MMWR)
  • First detected in early 2026 (CDC MMWR)
  • Classified as a variant under monitoring by ECDC (ECDC)

Nickname: Cicada variant

The nickname “Cicada” reportedly comes from its pattern of reappearance, like the insect, according to Clinikk. It is not an official CDC designation but has stuck in media coverage. Official health authorities like the CDC continue to use the lineage designation BA 3.2 (CDC MMWR).

Why this matters: knowing the official name helps when reading health alerts — the nickname is catchy, but the lineage number is what you’ll see on surveillance dashboards.

Is the new strain of COVID more serious?

Severity compared to Delta and earlier Omicron variants

  • No evidence of increased severity (Global Virus Network)
  • Generally milder than Delta (AARP)
  • High transmissibility but lower severity (Stony Brook Medicine)
  • Risk higher for immunocompromised and elderly (NewYork-Presbyterian)

Hospitalization and mortality data for BA 3.2

Hospitalization rates in regions where BA 3.2 is dominant remain low relative to prior waves, particularly among vaccinated populations. CDC MMWR data shows no signal of increased mortality.

The trade-off: BA 3.2 is easier to catch but less likely to put you in hospital — unless you are in a high-risk group. That makes personal risk assessment more nuanced.

How long does new COVID last?

Typical duration of symptoms for BA 3.2

  • Most recover in 3–7 days (Stony Brook Medicine, AARP)
  • Cough and fatigue may persist up to 2 weeks (NewYork-Presbyterian)
  • High-risk individuals may have longer illness (CDC MMWR)

Factors that affect recovery time

Vaccination status, age, underlying conditions, and whether antiviral treatment is used all influence recovery. For most healthy adults, the acute phase resolves within a week.

What this means: plan for a week of feeling off, with a tail of fatigue that can stretch. The key is to listen to your body and avoid rushing back.

How can I tell if I have COVID or a cold?

The overlap is so large that guessing rarely works, but a few patterns can tilt the odds.

Symptom COVID (BA 3.2) Common cold
Fever Common Rare
Sore throat Very common Common
Loss of taste/smell Possible but less common Very rare
Runny nose Common Common
Fatigue Often moderate to severe Mild
New cough Common Possible

When to test

The NHS recommends taking a rapid antigen test if you have symptoms and are at risk or need to protect others. At-home tests still detect BA 3.2 according to CDC.

The catch

The tests work, but timing matters. Test too early or too late and you might get a false negative. For best accuracy, test when symptoms are at their peak.

Official NHS guidance on distinguishing

The NHS advises that while fever and loss of taste/smell are more indicative of COVID, the only definitive way to distinguish is through testing. NewYork-Presbyterian echoes this: symptoms alone are unreliable.

The pattern: symptoms alone are unreliable. The only way to be sure is to test, especially if you are in a vulnerable group.

Should we be worried about the current COVID-19 variants?

Current risk assessment from ECDC and NHS

  • BA 3.2 is a variant under monitoring, not of concern (ECDC)
  • No current evidence of increased severity (Global Virus Network)
  • Vaccination still effective against severe disease (CDC MMWR)

Precautions recommended in 2026

Health authorities continue to recommend hand hygiene, good ventilation, staying home when ill, and keeping up to date with vaccinations. For overall health, supporting your liver may help recovery — learn more about what the liver does and how to take care of it.

The verdict: no cause for alarm, but the virus isn’t gone. A sensible, low-effort caution remains the smartest approach.

Here are the technical specs that public health labs use to track BA 3.2:

Specification Detail
Lineage BA 3.2 (Omicron sublineage, BA.1 derivative)
Spike protein changes 70–75 substitutions and deletions relative to JN.1 and LP.8.1 (CDC MMWR)
Detection by PCR Yes, standard PCR tests detect it (NewYork-Presbyterian)
Vaccine protection 2025-26 vaccines expected to offer partial protection; effectiveness being studied (CDC MMWR)
ECDC classification Variant under monitoring (VUM) (ECDC)
Common nickname Cicada (Clinikk)

Timeline signal

  • Early 2026: BA 3.2 first detected, designated variant under monitoring by ECDC (CDC MMWR)
  • Spring 2026: BA 3.2 becomes dominant strain in several regions; nicknamed Cicada (NewYork-Presbyterian)
  • May 2026: ECDC updates variant classification; BA 3.2 remains under monitoring (ECDC)
  • June 2026: NHS and other health bodies issue guidance on symptoms and duration (AARP)

Confirmed facts

  • BA 3.2 is an Omicron sublineage (CDC MMWR)
  • Common symptoms: sore throat, runny nose, cough, fatigue, fever (NewYork-Presbyterian)
  • Most recover in 3–7 days (Stony Brook Medicine)
  • Vaccination protects against severe disease (Global Virus Network)

What remains unclear

  • Whether BA 3.2 will cause a major winter wave (Global Virus Network)
  • Full immune escape profile (CDC MMWR)
  • Long-term post-COVID symptom rate specifically for this variant (AARP)
  • Precise growth advantage over other sublineages (ECDC)

“Current evidence does not indicate BA.3.2 is causing heightened public concern.”

— Global Virus Network (international coalition of virologists)

“BA 3.2 does not seem to cause new or unusual symptoms compared with other recent Omicron subvariants.”

— Stony Brook Medicine (academic medical center)

“The symptoms are similar to those of a cold and to those of other COVID variants.”

— NewYork-Presbyterian (major academic medical center)

For the average healthy adult in 2026, the choice is clear: keep a test kit at home, stay home when sick, but there is no need to panic. For the elderly or immunocompromised, early testing and antiviral treatment can still make a real difference. The virus has not disappeared, but its threat level has settled into something more manageable — as long as we stay sensible.

Additional sources

passionhealthphysicians.com, vaccineadvisor.com

Don't miss these

Frequently asked questions

What does BA 3.2 stand for?

BA 3.2 is a lineage designation for an Omicron sublineage of SARS-CoV-2. The “BA” refers to the Omicron lineage, and “3.2” indicates its position in the phylogenetic tree.

Is the Cicada variant more contagious than previous Omicron strains?

Early data suggest BA 3.2 is highly transmissible, but its growth advantage over other co-circulating sublineages is still being assessed by ECDC and CDC.

Does the current COVID vaccine protect against BA 3.2?

According to the CDC MMWR, the 2025-26 vaccines are based on JN.1 and LP.8.1 strains. BA 3.2 has 70-75 spike protein changes relative to those strains, which may reduce but not eliminate vaccine effectiveness against infection. Vaccination is still expected to provide strong protection against severe disease.

Can you get BA 3.2 if you had a prior Omicron infection?

Yes, prior infection does not guarantee immunity. Reinfection with BA 3.2 has been reported, though the risk may be lower shortly after infection.

What should I do if I think I have the new strain?

Take a rapid antigen test, stay home to avoid spreading it, and monitor your symptoms. If you are at high risk (elderly, immunocompromised, or with underlying conditions), contact your GP about antiviral treatments like Paxlovid.

Is there a specific treatment for BA 3.2?

There is no variant-specific treatment. Standard COVID-19 therapies, including antivirals and supportive care, are expected to remain effective. Always follow NHS or local health authority advice.

Are the at-home tests still effective for BA 3.2?

Yes, current rapid antigen tests detect BA 3.2. The CDC and FDA have confirmed that widely available tests work for circulating Omicron sublineages.

Related reading